MARKET

HSKA

HSKA

Heska
NASDAQ

Real-time Quotes | Nasdaq Last Sale

179.55
-0.04
-0.02%
After Hours: 179.55 0 0.00% 16:19 04/16 EDT
OPEN
181.80
PREV CLOSE
179.59
HIGH
181.80
LOW
177.79
VOLUME
43.67K
TURNOVER
--
52 WEEK HIGH
217.17
52 WEEK LOW
57.30
MARKET CAP
1.87B
P/E (TTM)
-104.0327
1D
5D
1M
3M
1Y
5Y
Heska Announces its Annual Meeting of Stockholders on May 5, 2021
Heska Corporation (NASDAQ: HSKA) ("Heska" or the "Company"), a leading provider of advanced veterinary diagnostic and specialty products, announces its 2021 Annual Meeting of Stockholders. The virtual event is scheduled for 9 a.m. MT/11 a.m. ET on Wednesda...
PR Newswire · 1d ago
What's in Store for Edwards Lifesciences (EW) in Q1 Earnings?
Zacks.com · 4d ago
Heska First Quarter 2021 Financial Results and Earnings Call Scheduled for May 6, 2021
Heska Corporation (NASDAQ: HSKA; "Heska" or the "Company"), a leading provider of advanced veterinary diagnostic and specialty products, will report its first quarter 2021 financial performance in a press release before the market opens on Thursday, May 6,...
PR Newswire · 04/08 13:00
Uptrend Call Working As Heska Corp Stock Rises 78.0% (HSKA)
SmarTrend identified an Uptrend for Heska Corp (NASDAQ:HSKA) on October 8th, 2020 at $106.95. In approximately 5 months, Heska Corp has returned 77.96% as of today's recent price of $190.33.
Comtex SmarTrend(R) · 03/03 17:49
Heska prices upsized equity offering at $186
Heska (HSKA) has priced its upsized public offering of 940,860 common shares at $186.00/share, for gross proceeds of ~$175M (from $150M).Underwriters' over-allotment is an additional 141,129 shares. Net proceeds will
Seekingalpha · 03/03 04:14
Heska: Offering Expected to Close on or About March 5 >HSKA
Heska: Offering Expected to Close on or About March 5 >HSKA
Dow Jones · 03/03 03:20
Heska: JPMorgan, Piper Sandler & Co. Are Bookrunning Managers for Offering >HSKA
Heska: JPMorgan, Piper Sandler & Co. Are Bookrunning Managers for Offering >HSKA
Dow Jones · 03/03 03:19
Heska: May Use Part of Proceeds to Fund Possible Investments in or Acquisitions of Businesses, Products or Technologies, or to Repay Debt >HSKA
Heska: May Use Part of Proceeds to Fund Possible Investments in or Acquisitions of Businesses, Products or Technologies, or to Repay Debt >HSKA
Dow Jones · 03/03 03:19
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of HSKA. Analyze the recent business situations of Heska through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average HSKA stock price target is 208.25 with a high estimate of 230.00 and a low estimate of 158.00.
EPS
Institutional Holdings
Institutions: 207
Institutional Holdings: 10.31M
% Owned: 98.95%
Shares Outstanding: 10.42M
TypeInstitutionsShares
Increased
43
431.65K
New
38
487.42K
Decreased
46
971.47K
Sold Out
9
125.75K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+0.15%
Healthcare Equipment & Supplies
+0.17%
Key Executives
Non-Executive Chairman/Independent Director
Scott Humphrey
President/Chief Executive Officer/Director
Kevin Wilson
Chief Financial Officer/Executive Vice President
Catherine Grassman
Chief Operating Officer/Executive Vice President
Nancy Wisnewski
Executive Vice President/Chief Administrative Officer/General Counsel/Secretary
Christopher Sveen
Executive Vice President
Eleanor Baker
Executive Vice President
Steven Eyl
Independent Director
Robert Antin
Independent Director
Stephen Davis
Independent Director
Mark Furlong
Independent Director
Joachim Hasenmaier
Independent Director
Sharon Larson
Independent Director
David Sveen
Independent Director
Bonnie Trowbridge
Declaration Date
Dividend Per Share
Ex-Div Date
09/12/2012
Dividend USD 0.1
09/26/2012
05/07/2012
Dividend USD 0.1
06/27/2012
02/22/2012
Dividend USD 0.1
03/28/2012
About HSKA
Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products. Its OVP segment includes private label vaccine and pharmaceutical production for cattle but also for other species, including equine, porcine, avian, feline and canine. All OVP products are sold by third parties under third-party labels. It focuses on supporting veterinarians in canine and feline healthcare space. It offers a line of veterinary blood testing and other instruments. It manufactures biological and pharmaceutical products for other animal health companies.

Webull offers kinds of Heska Corp stock information, including NASDAQ:HSKA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HSKA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HSKA stock methods without spending real money on the virtual paper trading platform.